We aimed to test treatment de-escalation in patients with a high IFN-γ signature gene expression score (IFN-γ score) in their baseline tumor biopsy, and treatment escalation in patients with a low IFN-γ score (e.g., administering alternative double or triple treatment combinations). The gene discussed is IFNG; the disease is neoplasm.